Viking Therapeutics Aktie
WKN DE: A12GD6 / ISIN: US92686J1060
01.10.2024 00:34:30
|
Why Viking Therapeutics Stock Topped the Market Today
Although Viking Therapeutics (NASDAQ: VKTX) is a busy company, on Monday its stock moved because of external news. A pundit reiterated his bullish take on the clinical-stage biotech, boosting sentiment on its shares and sending them nearly 3% higher in price. That was more than good enough to top the rising S&P 500 index, which closed the trading session up by 0.4%.Like many investors, Morgan Stanley analyst Michael Ulz sees vast potential for Viking's VK2735, an investigational weight-loss drug. Due largely to this, in his opinion, the biotech is an overweight (read: buy) at a price target of $105 per share. VK2735 has performed admirably in early- and mid-stage clinical testing, and should soon advance to a crucial and extensive phase 3 trial. If that goes well and the medication ends up winning Food and Drug Administration (FDA) approval, it would immediately be competitive with the hotly popular GLP-1 drugs Wegovy from Novo Nordisk and Eli Lilly's recently approved Zepbound. Continue readingWeiter zum vollständigen Artikel bei MotleyFool

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Viking Therapeutics Incmehr Nachrichten
Keine Nachrichten verfügbar. |
Analysen zu Viking Therapeutics Incmehr Analysen
Aktien in diesem Artikel
Viking Holdings Ltd Registered Shs | 40,49 | 1,86% |
|
Viking Therapeutics Inc | 21,89 | -0,09% |
|